National Evidence on the Use of Shared Decision Making in Prostate-Specific Antigen Screening

被引:78
|
作者
Han, Paul K. J. [1 ,2 ]
Kobrin, Sarah [3 ]
Breen, Nancy [4 ]
Joseph, Djenaba A. [5 ]
Li, Jun [5 ]
Frosch, Dominick L. [6 ,7 ]
Klabunde, Carrie N. [4 ]
机构
[1] Maine Med Ctr, Res Inst, Portland, ME 04101 USA
[2] Tufts Univ, Sch Med, Boston, MA 02111 USA
[3] Natl Canc Inst, Div Canc Control & Populat Sci, Behav Res Program, Rockville, MD USA
[4] Natl Canc Inst, Div Canc Control & Populat Sci, Appl Res Program, Rockville, MD USA
[5] Ctr Dis Control & Prevent, Atlanta, GA USA
[6] Palo Alto Med Fdn, Res Inst, Palo Alto, CA 94301 USA
[7] Univ Calif Los Angeles, Dept Med, Los Angeles, CA USA
关键词
prostate-specific antigen; mass screening; decision making; PRIMARY-CARE PHYSICIANS; RANDOMIZED CONTROLLED-TRIAL; INFORMED DECISIONS; SELF-REPORTS; HEALTH-CARE; CANCER; MEN; SERVICES; ACCURACY; CONCORDANCE;
D O I
10.1370/afm.1539
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
PURPOSE Recent clinical practice guidelines on prostate cancer screening using the prostate-specific antigen (PSA) test (PSA screening) have recommended that clinicians practice shared decision making-a process involving clinician-patient discussion of the pros, cons, and uncertainties of screening. We undertook a study to determine the prevalence of shared decision making in both PSA screening and nonscreening, as well as patient characteristics associated with shared decision making. METHODS A nationally representative sample of 3,427 men aged 50 to 74 years participating in the 2010 National Health Interview Survey responded to questions on the extent of shared decision making (past physician-patient discussion of advantages, disadvantages, and scientific uncertainty associated with PSA screening), PSA screening intensity (tests in past 5 years), and sociodemographic and health-related characteristics. RESULTS Nearly two-thirds (64.3%) of men reported no past physician-patient discussion of advantages, disadvantages, or scientific uncertainty (no shared decision making); 27.8% reported discussion of 1 to 2 elements only (partial shared decision making); 8.0% reported discussion of all 3 elements (full shared decision making). Nearly one-half (44.2%) reported no PSA screening, 27.8% reported low-intensity (less-than-annual) screening, and 25.1% reported high-intensity (nearly annual) screening. Absence of shared decision making was more prevalent in men who were not screened; 88% (95% CI, 86.2%-90.1%) of nonscreened men reported no shared decision making compared with 39% (95% CI, 35.0%-43.3%) of men undergoing high-intensity screening. Extent of shared decision making was associated with black race, Hispanic ethnicity, higher education, health insurance, and physician recommendation. Screening intensity was associated with older age, higher education, usual source of medical care, and physician recommendation, as well as with partial vs no or full shared decision making. CONCLUSIONS Most US men report little shared decision making in PSA screening, and the lack of shared decision making is more prevalent in nonscreened than in screened men. Screening intensity is greatest with partial shared decision making, and different elements of shared decision making are associated with distinct patient characteristics. Shared decision making needs to be improved in decisions for and against PSA screening.
引用
收藏
页码:306 / 314
页数:9
相关论文
共 50 条
  • [31] Prostate-specific antigen screening: pro
    Loeb, Stacy
    Catalona, William J.
    [J]. CURRENT OPINION IN UROLOGY, 2010, 20 (03) : 185 - 188
  • [32] National trends in the epidemiology of prostate cancer, 1973 to 1994: Evidence for the effectiveness of prostate-specific antigen screening - Comment
    Mettlin, C
    [J]. UROLOGY, 1998, 52 (03) : 448 - 449
  • [34] Further Evidence That Prostate-Specific Antigen Screening Reduces Prostate Cancer Mortality
    Stampfer, Meir J.
    Jahn, Jaquelyn L.
    Gann, Peter H.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (03)
  • [35] Screening for Prostate Cancer With the Prostate-Specific Antigen Test A Review of Current Evidence
    Hayes, Julia H.
    Barry, Michael J.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (11): : 1143 - 1149
  • [36] The association between physician trust and prostate specific antigen screening: Implications for shared decision making.
    Klaassen, Zachary William Abraham
    Wallis, Christopher J. D.
    Goldberg, Hanan
    Chandrasekar, Thenappan
    Fleshner, Neil Eric
    Finelli, Antonio
    Kulkarni, Girish S.
    Satkunasivam, Raj
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [37] Primary Care Providers’ Intended Use of Decision Aids for Prostate-Specific Antigen Testing for Prostate Cancer Screening
    Sun Hee Rim
    Ingrid J. Hall
    Greta M. Massetti
    Cheryll C. Thomas
    Jun Li
    Lisa C. Richardson
    [J]. Journal of Cancer Education, 2019, 34 : 666 - 670
  • [38] Primary Care Providers' Intended Use of Decision Aids for Prostate-Specific Antigen Testing for Prostate Cancer Screening
    Rim, Sun Hee
    Hall, Ingrid J.
    Massetti, Greta M.
    Thomas, Cheryll C.
    Li, Jun
    Richardson, Lisa C.
    [J]. JOURNAL OF CANCER EDUCATION, 2019, 34 (04) : 666 - 670
  • [39] Screening for prostate cancer with the prostate-specific antigen test - Are patients making informed decisions?
    O'Dell, KJ
    Volk, RJ
    Cass, AR
    Spann, SJ
    [J]. JOURNAL OF FAMILY PRACTICE, 1999, 48 (09): : 682 - 688
  • [40] Use of Baseline Prostate-Specific Antigen Measurements to Personalize Prostate Cancer Screening
    Loeb, Stacy
    [J]. EUROPEAN UROLOGY, 2012, 61 (05) : 875 - 876